Table 4.
Proportions of Participants With Postvaccination Antibody Titers ≥40, ≥80, and ≥160 in Each Group
| Assay | Strain | Vaccination Group | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Standard-dose QIV, n = 200 | MF59-adjuvantedTIV, n = 200 | High-doseTIV, n = 200 | Recombinant-HA QIV, n = 200 | ||||||
| Prop. | (95% CI) | Prop. | (95% CI) | Prop. | (95% CI) | Prop. | (95% CI) | ||
| Postvaccination (D30) titer ≥40 | |||||||||
| HAI | A/Michigan/45/2015 (H1N1) | 73% | (66–79%) | 82%* | (76–87%) | 83%* | (77–88%) | 76% | (69–81%) |
| HAI | A/Hong Kong/4801/2014 (H3N2) | 94% | (90–97%) | 96% | (92–98%) | 96% | (92–98%) | 96% | (92–98%) |
| MN | A/Hong Kong/4801/2014 (H3N2) | 78% | (72–84%) | 85% | (79–90%) | 82% | (77–87%) | 94%* | (90–97%) |
| HAI | B/Brisbane/60/2008 | 84% | (78–88%) | 88% | (83–93%) | 90% | (85–94%) | 88% | (82–92%) |
| HAI | B/Phuket/3073/2013a | 94% | (90–97%) | 77%* | (71–83%) | 78%* | (72–84%) | 90% | (86–94%) |
| Postvaccination (D30) titer ≥80 | |||||||||
| HAI | A/Michigan/45/2015 (H1N1) | 54% | (47–61%) | 64%* | (57–71%) | 69%* | (62–75%) | 62% | (54–68%) |
| HAI | A/Hong Kong/4801/2014 (H3N2) | 81% | (75–86%) | 88%* | (83–93%) | 88% | (82–92%) | 92%* | (8%–96%) |
| MN | A/Hong Kong/4801/2014 (H3N2) | 63% | (56–70%) | 72% | (65–78%) | 74%* | (67–79%) | 88%* | (83–92%) |
| HAI | B/Brisbane/60/2008 | 69% | (62–75%) | 70% | (63–76%) | 78% | (71–83%) | 64% | (57–71%) |
| HAI | B/Phuket/3073/2013a | 76% | (69–81%) | 58%* | (51–65%) | 58%* | (51–65%) | 77% | (71–83%) |
| Postvaccination (D30) titer ≥160 | |||||||||
| HAI | A/Michigan/45/2015 (H1N1) | 35% | (28–42%) | 45%* | (38–52%) | 55%* | (48–62%) | 46%* | (39–53%) |
| HAI | A/Hong Kong/4801/2014 (H3N2) | 64% | (56–70%) | 72% | (66–79%) | 75%* | (68–81%) | 81%* | (75–86%) |
| MN | A/Hong Kong/4801/2014 (H3N2) | 48% | (41–56%) | 54% | (47–61%) | 58% | (51–65%) | 74%* | (68–80%) |
| HAI | B/Brisbane/60/2008 | 40% | (34–48%) | 44% | (37–52%) | 54%* | (46–61%) | 39% | (32–46%) |
| HAI | B/Phuket/3073/2013a | 52% | (45–59%) | 32%* | (26–39%) | 33%* | (27–40%) | 56% | (49–63%) |
*
Significant differences in comparison to standard-dose QIV.
Abbreviagtions: D, day; HA, hemagglutinin; HAI, hemagglutination inhibition assay; MN, microneutralization assay; Prop., proportion; QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine.
a
Note that a B/Yamagata lineage virus was not included in the MF59-adjuvanted TIV and the high-dose TIV.